The CenterWatch Weekly, December 19, 2016
Center Point’s siteless technology disrupts CRO sector, offers more humanistic, safer approach
In a series of announcements this week, Center Point Clinical Services unveiled what it calls the first siteless technology model for pharmaceutical trial research in the CRO industry. The announcement appears to come as a surprise within the CRO industry, perhaps even a shock. Only one of several CROs contacted for comment responded to CenterWatch inquires.
CRISPR/Cas9 market expanding, but questions remain
Recent announcements reflect the enormous excitement and activity surrounding CRISPR/Cas9. Biotech company Intellia Therapeutics announced the opening of its new headquarters in Cambridge, Massachusetts, in early December. The company is pioneering therapeutic applications of CRISPR/Cas9, a revolutionary genome editing technology that researchers hope will eventually generate treatments for a broad range of diseases.
To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.